Breaking News

Avid Bioservices Opens Early Phase Center of Excellence in CA

Expands Avid's development footprint and strengthens its ability to provide end-to-end services from cell line development through commercial manufacturing.

Author Image

By: Charlie Sternberg

Associate Editor

Avid Bioservices Inc., a dedicated biologics CDMO, has opened its new Early Phase Center of Excellence, a 78,000 square foot facility located in Costa Mesa, California. Purpose built to support early clinical programs, the new center expands Avid’s development footprint and strengthens the company’s ability to provide end-to-end services from cell line development through commercial manufacturing.

Designed to accelerate clients’ early development timelines, the facility brings together Avid’s core scientific and technical capabilities including:

  • Cell line development
  • Upstream and downstream process and analytical development
  • IND enabling analytical method qualification, and testing
  • Early formulation development and characterization
  • Integrated tech transfer into Avid’s CGMP manufacturing facilities

The Early Phase Center of Excellence houses experienced, hands on scientific and manufacturing teams, established platform processes, and harmonized quality systems aligned with Avid’s commercial manufacturing facility. This alignment ensures consistency, eliminates rework, and provides a smooth progression as programs advance from preclinical through to commercial supply.

The Costa Mesa expansion enhances Avid’s overall capacity to support a wide range of biologics including monoclonal antibodies, recombinant proteins, and other complex modalities. The center’s integrated workflows and technology platforms are engineered to reduce program risk, compress timelines, and ensure phase appropriate development from the earliest stages.

“Our mission is to strengthen early drug development here in the U.S., accelerating the journey from scientific discovery to patient impact,” said Kenneth Bilenberg, CEO of Avid Bioservices. “The industry has been asking for a U.S.-based development and manufacturing powerhouse that combines speed, quality, and scientific rigor and we built it.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters